Biotech company ExpreS2ion Biotechnologies today announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion's Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production.

The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford. The platform will be used by various research teams to address expression of complex and "difficult-to-make" proteins.